GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Common Stock

Savara (STU:YB4P) Common Stock : €0.13 Mil (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Savara Common Stock?

Savara's quarterly common stock stayed the same from Sep. 2023 (€0.13 Mil) to Dec. 2023 (€0.13 Mil) but then increased from Dec. 2023 (€0.13 Mil) to Mar. 2024 (€0.13 Mil).

Savara's annual common stock increased from Dec. 2021 (€0.10 Mil) to Dec. 2022 (€0.11 Mil) and increased from Dec. 2022 (€0.11 Mil) to Dec. 2023 (€0.13 Mil).


Savara Common Stock Historical Data

The historical data trend for Savara's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Common Stock Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.10 0.11 0.13

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.11 0.13 0.13 0.13

Savara Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Savara (STU:YB4P) Business Description

Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara (STU:YB4P) Headlines

No Headlines